Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tebentafusp
- Development stage
- Approved
- Lead developer
- Immunocore
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Tebentafusp is a first-in-class bispecific T-cell receptor (TCR) fusion protein immunotherapy designed to treat unresectable or metastatic uveal melanoma in HLA-A*02:01-positive adults. It consists of an engineered TCR domain that specifically binds to a gp100 peptide presented by HLA-A*02:01 on melanoma cells, fused to an anti-CD3 single-chain variable fragment (scFv) effector domain. This structure enables the drug to physically bridge and activate CD3+ T cells against tumor cells expressing gp100, leading to targeted cytotoxicity and tumor cell death through the release of perforins and granzymes. Tebentafusp is only effective in patients who are positive for the HLA-A*02:01 antigen[1][2][6][7]. Developed by Immunocore, it was shown in clinical trials to improve overall survival compared with standard therapies for metastatic uveal melanoma[6][7].
- Brand names
- Kimmtrak
- Other names
- tebentafusp-tebn
02
Targets
CD3 (T-cell surface glycoprotein CD3)PMEL (Melanocyte Protein PMEL)
Beyond the preview
Go deeper on tebentafusp.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tebentafusp.